All Posts By

laurabbook@gmail.com

ESMO Annals of Oncology
ResearchTreatments

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

*May 2025* Highlights •Patients with EGFR-mutated NSCLC that progresses after osimertinib treatment need additional treatment options. •c-Met protein expression correlates with osimertinib resistance. •Teliso-V is an antibody–drug conjugate that targets c-Met protein overexpression. •Teliso-V + osimertinib had promising activity in EGFR-mut, c-Met protein-overexpressing NSCLC post-osimertinib progression. •The combination of Teliso-V…
lung cancer advocacy
Advocacy

Getting Started in Lung Cancer Advocacy

*February 2025* The lung cancer community has a dire need for more advocates in order for us (both survivors and caregivers) to have more voice and involvement in research projects, clinical trials, and government research funding. Before you make the deep dive into advocacy, here are some networks and recorded…
EGFR Resister Logo
Research

2021 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awards Update

*January 2025* 2021 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Award – Dr. Christine Lovly progress update Dr. Christine Lovly from Vanderbilt University is studying how EGFR+ NSCLC cells become resistant to osimertinib, a tyrosine kinase inhibitor currently used as the first treatment option for EGFR+ lung cancer. Specifically, her…
laurabbook@gmail.com
January 6, 2025
EGFR Resister Logo
Research

2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Award Year 1 Progress Update

*January 2025* Drug-tolerant persister cells (DTPCs) are cancer cells that survive drug treatment such as tyrosine kinase inhibitors. These cells are a key reason why EGFR-positive NSCLC (EGFR+ NSCLC) can come back after treatment. 2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awardees are studying how to target DTPCs. Dr.…
laurabbook@gmail.com
January 6, 2025